<DOC>
	<DOC>NCT00491140</DOC>
	<brief_summary>The primary objective is to identify molecular features predicting response or resistance to cetuximab</brief_summary>
	<brief_title>Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab</brief_title>
	<detailed_description>Secondary objective is to investigate association of genomic status of EGFR and HER-2 genes with clinical outcome, including objective response, time to progression and survival</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically confirmed diagnosis of colorectal cancer with available tumor tissue and clinical data; presence of at least one measurable lesion. Less than 3 weeks after completion of previous radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>EGFR</keyword>
	<keyword>KRAS</keyword>
	<keyword>BRAF</keyword>
	<keyword>MET</keyword>
	<keyword>IGFR1</keyword>
</DOC>